Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1802561 | 0.86 | ALDH1A1 (0.75) | ALDH1A1KMT2AMEN1HIF1ANPSR1 | |
| SCHEMBL7956531 | 0.85 | KMT2A (0.68) | ALDH1A1KMT2AMEN1HIF1ANPSR1 | |
| SCHEMBL19248825 | 0.85 | KMT2A (0.68) | ALDH1A1KMT2AMEN1HIF1ANPSR1 | |
| SCHEMBL7954452 | 0.84 | NPSR1 (0.67) | ALDH1A1KMT2AMEN1HIF1ANPSR1 | |
| SCHEMBL5145231 | 0.84 | LMNA (0.68) | ALDH1A1KMT2AMEN1HIF1ANPSR1 | |
| SCHEMBL4266953 | 0.84 | LMNA (0.68) | ALDH1A1KMT2AMEN1HIF1ANPSR1 | |
| SCHEMBL2517739 | 0.83 | ALDH1A1 (0.65) | ALDH1A1KMT2AMEN1HIF1ANPSR1 | |
| SCHEMBL19717846 | 0.83 | ALDH1A1 (0.65) | ALDH1A1KMT2AMEN1HIF1ANPSR1 | |
| SCHEMBL5512491 | 0.83 | ALDH1A1 (0.65) | ALDH1A1KMT2AMEN1HIF1ANPSR1 | |
| SCHEMBL19783672 | 0.82 | PPARA (0.61) | ALDH1A1KMT2AMEN1HIF1ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2409569-B1 | Method for administering GLP-1 molecules | EMISPHERE TECH INC (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-1478233-B1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECH INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2015-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-8492330-B2 | Formulation comprising GLP-1 | EMISPHERE TECHNOLOGIES, INC. (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2409569-A2 | Method for administering GLP-1 molecules | Emisphere Technologies, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-7939494-B2 | Method for administering GLP-1 molecules | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7939494-B2 | Method for administering GLP-1 molecules | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | NOVO NORDISK NORTH AMERICA OPERATIONS A/S (DK) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150202296-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | ALDH1A1 3386/4885KMT2A 4222/4885MEN1 776/4885 |
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | ALDH1A1 3386/4885KMT2A 4222/4885MEN1 776/4885 |
| US-20090286735-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | ALDH1A1 3386/4885KMT2A 4222/4885MEN1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.